AU2004280638A1 - Methods for treating diseases and conditions with inverse agonists and for screening for agents acting as inverse agonists - Google Patents

Methods for treating diseases and conditions with inverse agonists and for screening for agents acting as inverse agonists Download PDF

Info

Publication number
AU2004280638A1
AU2004280638A1 AU2004280638A AU2004280638A AU2004280638A1 AU 2004280638 A1 AU2004280638 A1 AU 2004280638A1 AU 2004280638 A AU2004280638 A AU 2004280638A AU 2004280638 A AU2004280638 A AU 2004280638A AU 2004280638 A1 AU2004280638 A1 AU 2004280638A1
Authority
AU
Australia
Prior art keywords
receptors
adrenergic
agonist
receptor
inverse agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004280638A
Other languages
English (en)
Other versions
AU2004280638A2 (en
Inventor
Richard A. Bond
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inverseon Inc
Original Assignee
Inverseon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inverseon Inc filed Critical Inverseon Inc
Publication of AU2004280638A1 publication Critical patent/AU2004280638A1/en
Publication of AU2004280638A2 publication Critical patent/AU2004280638A2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Indole Compounds (AREA)
AU2004280638A 2003-10-09 2004-10-08 Methods for treating diseases and conditions with inverse agonists and for screening for agents acting as inverse agonists Abandoned AU2004280638A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US51025003P 2003-10-09 2003-10-09
US60/510,250 2003-10-09
US55579704P 2004-03-23 2004-03-23
US60/555,797 2004-03-23
PCT/US2004/033530 WO2005035731A2 (en) 2003-10-09 2004-10-08 Methods for treating diseases and conditions with inverse agonists and for screening for agents acting as inverse agonists

Publications (2)

Publication Number Publication Date
AU2004280638A1 true AU2004280638A1 (en) 2005-04-21
AU2004280638A2 AU2004280638A2 (en) 2005-04-21

Family

ID=34437322

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2004280638A Abandoned AU2004280638A1 (en) 2003-10-09 2004-10-08 Methods for treating diseases and conditions with inverse agonists and for screening for agents acting as inverse agonists
AU2004279438A Abandoned AU2004279438A1 (en) 2003-10-09 2004-10-08 Methods for treating diseases and conditions with inverse agonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2004279438A Abandoned AU2004279438A1 (en) 2003-10-09 2004-10-08 Methods for treating diseases and conditions with inverse agonists

Country Status (7)

Country Link
US (1) US9539221B2 (enExample)
EP (2) EP1684764A2 (enExample)
JP (1) JP2007527409A (enExample)
AU (2) AU2004280638A1 (enExample)
CA (2) CA2544611A1 (enExample)
IL (1) IL174765A0 (enExample)
WO (2) WO2005035731A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
EA009985B1 (ru) 2003-03-10 2008-04-28 Никомед Гмбх Новый способ получения рофлумиласта
WO2005089741A2 (en) * 2004-03-17 2005-09-29 Sosei R&D Ltd. The treatment of inflammatory disorders and pain using beta-aminoalcohols
JP2007536350A (ja) * 2004-05-10 2007-12-13 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 肺気腫の予防又は治療のためのロフルミラストの使用
US8691877B2 (en) 2004-10-15 2014-04-08 Palo Alto Investors Methods and compositions for treating a disease condition in a subject
ES2421916T3 (es) 2005-03-16 2013-09-06 Nycomed Gmbh Forma farmacéutica de sabor enmascarado que contiene roflumilast
US20090214643A1 (en) * 2005-07-19 2009-08-27 Franklin Amie E Improved pharmacokinetic profile of beta-adrenergic inverse agonists for the treatment of pulmonary airway diseases
AU2010282202B2 (en) * 2009-08-12 2014-10-09 Isonea Australia Pty Ltd Determining dynamic airway response in a subject
DK2665741T3 (en) * 2011-01-10 2019-04-29 Invion Inc APPLICATION OF BETA-ADRENERGE INVERSE AGONISTS FOR SMOKE CLEANING
US11382513B2 (en) 2016-11-08 2022-07-12 Palo Alto Investors Methods and compositions for treating a condition in a subject
US10744087B2 (en) 2018-03-22 2020-08-18 Incarda Therapeutics, Inc. Method to slow ventricular rate
US10947196B2 (en) 2019-03-27 2021-03-16 Curasen Therapeutics, Inc. Beta adrenergic agonist and methods of using the same
US11607395B2 (en) 2019-12-18 2023-03-21 Curasen Therapeutics, Inc. Methods for improving neurological diseases and disorders
CA3211268A1 (en) * 2021-03-09 2022-09-15 Chronic Airway Therapeutics Limited Use of nadolol to treat chronic obstructive pulmonary disease by blockage of the arrestin-2 pathway
US12616667B2 (en) 2021-11-15 2026-05-05 Curasen Therapeutics, Inc. Compositions and methods for improving neurological diseases and disorders
US20260232607A1 (en) * 2022-06-21 2026-08-13 Curasen Therapeutics, Inc. Compositions and methods involving isolated compounds
WO2023250332A1 (en) * 2022-06-21 2023-12-28 Curasen Therapeutics, Inc. Compositions and methods involving isolated compounds
CN116199596B (zh) * 2023-03-06 2025-03-25 梯尔希（南京）药物研发有限公司 一种特布他林代谢物的制备方法
AU2024234602A1 (en) * 2023-03-13 2025-10-30 Chronic Airway Therapeutics Limited USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US36547A (en) * 1862-09-23 Improvement in locks
US4428926A (en) * 1981-12-18 1984-01-31 Key Pharmaceuticals, Inc. Sustained release propranolol system
US5316759A (en) * 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
US4769372A (en) * 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US5116867A (en) * 1989-06-30 1992-05-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services D-propranolol as a selective adenosine antagonist
US5352680A (en) * 1992-07-15 1994-10-04 Regents Of The University Of Minnesota Delta opioid receptor antagonists to block opioid agonist tolerance and dependence
US5633259A (en) * 1992-09-21 1997-05-27 United Biomedical, Inc. Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5472943A (en) * 1992-09-21 1995-12-05 Albert Einstein College Of Medicine Of Yeshiva University, Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
US20010006967A1 (en) * 1992-09-21 2001-07-05 Stanley M. Crain Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists
USRE36547E (en) 1992-09-21 2000-02-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
US6096756A (en) * 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US6673558B1 (en) * 1992-09-30 2004-01-06 Richard G. Lanzara Drug compositions to prevent desensitization of cellular receptors
US6593094B2 (en) * 1992-09-30 2003-07-15 Richard G. Lanzara Compositions to enhance the efficacy and safety of bio-pharmaceutical drugs
US5597699A (en) * 1992-09-30 1997-01-28 Lanzara; Richard G. Method for determining drug compositions to prevent desensitization of cellular receptors
US5585348A (en) * 1993-02-10 1996-12-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Use of excitatory opioid receptor antagonists to prevent growth factor-induced hyperalgesia
AU2068797A (en) * 1996-01-29 1997-08-20 Edward Mendell Co. Inc. Sustained release excipient
JPH10251147A (ja) 1997-03-06 1998-09-22 Akira Matsumori 炎症性疾患の予防・治療剤
US6284800B1 (en) * 1997-03-13 2001-09-04 Baker Norton Pharmaceuticals, Inc. Methods and compositions for treatment of asthma
US6541209B1 (en) * 1997-04-14 2003-04-01 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
US6420541B1 (en) * 1998-04-14 2002-07-16 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
US6555339B1 (en) * 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
NZ505651A (en) * 1998-01-16 2003-08-29 Takeda Chemical Industries Ltd Sustained release composition comprising biologically active substance, hydroxynaphthoic acid and biodegradable polymer
US6653086B1 (en) * 1998-04-14 2003-11-25 Arena Pharmaceuticals, Inc. Endogenous constitutively activated G protein-coupled orphan receptors
US6107324A (en) * 1998-04-14 2000-08-22 Arena Pharmaceuticals Inc. 5-HT2A receptor inverse agonists
US6218402B1 (en) * 1998-06-10 2001-04-17 Arena Pharmaceuticals, Inc. Acetylcholine enhancers
US6140509A (en) * 1998-06-26 2000-10-31 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
US6420563B1 (en) * 1998-07-31 2002-07-16 Arena Pharmaceuticals, Inc. Small molecule modulators of G protein-coupled receptor six
US6627632B2 (en) * 1998-12-14 2003-09-30 Cellegy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
US6150393A (en) * 1998-12-18 2000-11-21 Arena Pharmaceuticals, Inc. Small molecule modulators of non-endogenous, constitutively activated human serotonin receptors
US6194382B1 (en) * 1999-03-03 2001-02-27 Albert Einstein College Of Medicine Of Yeshiva University Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
US6765010B2 (en) * 1999-05-06 2004-07-20 Pain Therapeutics, Inc. Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects
CA2402392A1 (en) * 2000-04-07 2001-10-18 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated known g protein-coupled receptors
AU2001292897A1 (en) 2000-09-21 2002-04-02 Richard Agustin Bond Novel therapy
YU33103A (sh) * 2000-10-31 2006-05-25 Boehringer Ingelheim Pharma Gmbh. & Co.Kg. Formulacija rastvora za inhalaciju sa soli tiotropijuma
US7018812B2 (en) * 2000-11-03 2006-03-28 Duke University Modified G-protein coupled receptors
JP2005500258A (ja) * 2001-03-23 2005-01-06 アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ Ｇｍ１ガングリオシドを阻害することによる、鎮痛効力を増大し、そして、ニ峰作用性オピオイドアゴニストの有害な興奮性効果を減弱する方法。
AU2002309196A1 (en) * 2001-06-26 2003-01-08 Decode Genetics Ehf. Nucleic acids encoding olfactory receptors
US7149574B2 (en) * 2003-06-09 2006-12-12 Palo Alto Investors Treatment of conditions through electrical modulation of the autonomic nervous system

Also Published As

Publication number Publication date
WO2005035731A2 (en) 2005-04-21
EP1684764A2 (en) 2006-08-02
CA2544611A1 (en) 2005-04-21
WO2005035731A3 (en) 2006-01-12
AU2004279438A2 (en) 2005-04-21
US20080254022A1 (en) 2008-10-16
AU2004279438A1 (en) 2005-04-21
CA2544733A1 (en) 2005-04-21
IL174765A0 (en) 2008-04-13
US9539221B2 (en) 2017-01-10
AU2004280638A2 (en) 2005-04-21
EP1677778A2 (en) 2006-07-12
JP2007527409A (ja) 2007-09-27
WO2005034871A3 (en) 2005-11-24
WO2005034871A2 (en) 2005-04-21

Similar Documents

Publication Publication Date Title
AU2004280638A2 (en) Methods for treating diseases and conditions with inverse agonists and for screening for agents acting as inverse agonists
US20100286224A1 (en) Method of treating airway diseases with beta-adrenergic inverse agonists
US20070276024A1 (en) Methods for Treating Diseases and Conditions with Inverse Agonists and for Screening for Agents Acting as Inverse Agonists
US20240180854A1 (en) Use of beta-adrenergic inverse agonists for smoking cessation
KR20050106038A (ko) 심장질환 및 신장질환의 치료를 위한 아데노신 ａ1 수용체길항제
WO2008002929A2 (en) Heterologous cross-sensitization for improved agonist activity
US20250017878A1 (en) Use of nadolol to treat chronic obstructive pulmonary disease by blockage of the arrestin-2 pathway
JP2024180674A (ja) 薬物依存またはアルコール依存を処置するための方法
CN114159450A (zh) 原人参二醇类化合物在治疗疼痛和成瘾物质躯体依赖、精神依赖和成瘾的用途
EP2938329A1 (en) Methods and compositions for administration of oxybutynin
RU2855994C2 (ru) Сложные эфиры монтелукаста и фармацевтические композиции, содержащие указанные соединения
HK1197916A (en) Use of beta-adrenergic inverse agonists for smoking cessation
HK1197916B (en) Use of beta-adrenergic inverse agonists for smoking cessation
WO2004087151A1 (ja) 医薬組成物
JP2003504412A (ja) ＩｇＥをダウンレギュレーションするための小ペプチドおよび方法

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 09 MAY 2006

MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period